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Pathogenesis
Foot infections are actually skin and soft tissue infections
of the lower extremities. Infection of the dermis is cate-
gorized as acute dermatitis and that of subcutaneous tissues
as soft tissue infection (cellulitis). In this section, the latter
is summarized. For cases in which gas bubbles are recog-
nized in lower extremity tissues on X-ray examination, and
when bony changes are seen, i.e., gas gangrene and nec-
rotizing fasciitis, which involve infection invading the
fascia and the muscle layer, and osteomyelitis, are
addressed in other sections.
Foot infections often present with a past history of
contamination with bacteria due to factors such as
injury, burn, ulcer, tinea pedis, ingrown nail, insect
bites, surgery, etc., but in many cases the causes are
unclear. The infected lesion in the early stage shows
diffuse redness with heat sensation, a locally swollen
surface and local tenderness. Foot infections commonly
occur in the area ranging from the foot to the leg. The
area spreads to upper part with the spread of inﬂam-
mation. When the inﬂammation is superﬁcial, it is
demarcated (the margin is distinct) and protuberance is
frequently associated with inﬂammation. This superﬁcial
inﬂammation shows localized small eruptions, but map-
like erythema is quite common. Expansion and pro-
gression of the infection lead to abscess formation. In
cases in which the infected lesion expands rapidly, the
prognosis is poor. When the infection spreads via lym-
phatic vessels from the infected lesion, red erythema
spreads craniad toward the inguinal region. With
expansion of the infected lesion, systemic signs and
symptoms such as pyrexia, leukocytosis, high C-reactive
protein (CRP) levels, and so on, appear (Table 1).
Risk factors for foot infection are impaired immune
responses at local sites and systemically, blood ﬂow distur-
bances, lymph congestion and the existence of foreign bodies.
Diabetes mellitus (DM) is clearly a major risk factor.
Since immunological competence is decreased by persis-
tent hyperglycemia, microscopic infected lesions become
refractory, and the infection tends to accelerate without
treatment of diabetic neuropathy. With regard to the
characteristics of DM-induced infection, the association of
arteriosclerosis obliterans, etc. with the infection contrib-
utes to the development of tissue necrosis and ulceration,
thereby increasing the severity of the infection.
Another risk factor is blood ﬂow disturbances in the
peripheral artery and those due to venous congestion of the
lower extremities. The blood ﬂow disturbances are fre-
quently associated with DM and hemodialysis. The affec-
ted site is reddish purple in color, and the risks of infection
developing and spreading are increased by tissue distur-
bances (ischemia, necrosis, etc.).
Lymph ﬂow insufﬁciency, due to stenosis (narrowing)
and occlusion of the lymphatic vessels of the lower
extremities, is also a risk factor. Since tissue ﬂuid and lymph
are retained, rather than ﬂowing, elimination of bacteria is
disturbed and immunological competence thereby decrea-
ses, and complement deﬁciency and so on are also recog-
nized [1]. Attention should be paid to the possibility of latent
lymphedema. Once an infection develops, lymph retention is
accelerated and worsens [2, 3].
Causative bacteria
In general, resident ﬂora of the skin, i.e., aerobic Gram-
positive cocci (coagulase-negative Staphylococcus aureus,
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a-hemolytic Streptococcus, Corynebacterium species, etc.),
frequently cause infections in healthy persons, but these
infections are mild. In the presence of abnormalities
including rough skin, veroderma (severe dry skin), and
chapping and in the presence of the aforementioned risk
factors, aerobic Gram-positive cocci with high toxicity
(S. aureus, b-hemolytic Streptococcus) and aerobic Gram-
negative bacilli (Enterobacteriaceae, etc.) are likely to be
isolated [4–6]. Severe infection is associated with adverse
host conditions (mixed infections with resistant bacteria
including MRSA and Pseudomonas aeruginosa and tissue
necrosis) in the long-term course of the infection and
during the use of antimicrobial agents, leading to isolation
of anaerobic bacteria (polymicrobial infections) [7, 8]. In
DM patients the rate of isolation of anaerobic bacteria is as
high as 74–95% [8, 9]. Many patients with anaerobic iso-
lates have polymicrobial infections (Table 2) [9], and the
isolation rate is 35–85% [10–15]. The total number of
bacterial species (including aerobes) per specimen is as
large as 4.1–5.8. Of the anaerobic bacteria, Gram-positive
bacteria are predominantly Peptostreptococcus species,
Finegoldia species, Parvimonas species and Anaerococcus
species, and Gram-negative bacteria predominantly Bac-
teroides species and Prevotella species. The type and fre-
quency of the isolates are similar to those for children
(pediatric cases) as well [16].
Antimicrobial therapy
Empiric therapy
When a foot infection develops, it is ﬁrst treated empiri-
cally. On this occasion, the selection and method of anti-
microbial drug use vary with the severity of the infected
lesion.
Mild
Oral antimicrobial agents with a narrow spectrum are
administered for aerobic Gram-positive cocci, particularly
targeting S. aureus.
In the presence of risk factors such as DM, antimicrobial
agents (ﬂuoroquinolones), exerting actions on aerobic
Gram-positive cocci and aerobic Gram-negative bacilli, are
administered [17].
Moderate
Oral antimicrobial agents (ﬂuoroquinolones, CLDM) [4, 8,
18] are administered, or antimicrobial agents are intrave-
nously injected for a short time (1–7 days), and thereafter
Table 1 Deﬁnitions of mild, moderate and severe foot infections
Mild Extremely localized cellulitis
and superﬁcial abscess
Moderate Cellulitis of a relatively wide-ranging
area caudad from the knee
Severe Cellulitis of a wider ranging area
craniad from the knee,
spread of inﬂammation
to deep soft tissue
Abscess of the deep tissue
Rapidly expanding cellulites
Dermal necrosis
Association of lymphangitis
Systemic inﬂammatory
response syndrome (SIRS)
Table 2 Isolates from infectious lesions of the foot in diabetic
patients
Bacterial species The number of isolates
Aerobic bacteria 607
Gram-positive bacilli 402
Staphylococcus aureus 113
Streptococcus species 97
Enterococcus species 73
Coagulase-negative Staphylococcus 66
Other Gram-positive cocci 21
Gram-positive rods 32
Gram-negative bacilli 205
Proteus species 46
Enterobacter species 27
Escherichia coli 25
Klebsiella species 21
Pseudomonas aeruginosa 20
Other Gram-negative rods 64
Gram-negative cocci 2
Anaerobic bacteria 278
Gram-positive bacilli 155
Peptostreptococcus species
114
Finegoldia species
Parvimonas species
Anaerococcus species
Clostridium species 22
Other Gram-positive cocci 19
Gram-negative bacilli 109
Bacteroides fragilis group 45
Other Bacteroides species
54
Prevotella species
Other Gram-negative anaerobic bacteria 10
Uncategorizable anaerobic bacteria 14
Total 885
Modiﬁed from Ref. [9]
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the patient is switched to oral drugs. As antimicrobial
agents for intravenous injection, the following are selected:
cephamycins, oxacephems and b-lactamase inhibitor
combination drugs and carbapenems [19–21]. Moderate
cases are treated on an outpatient basis, as a rule, but if the
occasion demands, on an inpatient basis.
Severe
Antimicrobial agents are administered intravenously for
inpatient treatment. Some b-lactams, i.e., carbapenems,
cephamycins, oxacephems, and b-lactamase inhibitor
combination drugs [19–21], or ﬂuoroquinolones [18, 22]
are selected as antimicrobial agents. The former four drugs
are used in the presence of systemic symptoms and for
wide-ranging infectious lesions. When the infection is
extremely severe, each drug is administered 3–4 times a
day. Each of ﬂuoroquinolones is administered twice a day.
Some reports have shown the frequency of anaerobe
isolation to be increased during treatment. It is therefore
important to select antimicrobial agents, which exert ade-
quate antimicrobial activity against anaerobic bacteria from
the beginning of the treatment [9].
Particular attention is needed for patients with risk
factors, partly because localized symptoms progress to
systemic symptoms within several hours and partly because
they are likely to have an early onset of worsening infec-
tion severity because of the association of disseminated
intravascular coagulation (DIC).
Implementation of bacterial culture
Tissue and pus specimens are collected, and blood is cul-
tured, depending on the situation. In the presence of
retention of pus and necrotic tissue and in the absence of
clinical efﬁcacy, bacterial collection is necessary. When no
pus is obtained by puncture aspiration, it is desirable for
specimens to be collected from the margin of the infected
lesion [23]. Samples should be collected from the deepest
possible layer, because samples from the shallower layers
may have been contaminated and the bacterial species
actually necessitating treatment cannot always be col-
lected. In the case of collecting anaerobic bacterial speci-
mens particularly, they must be collected from the deepest
feasible layer.
Changes in antimicrobial agents
In the case of uncontrollable infection
When an infection shows no indications of amelioration
after 3–7 days of antimicrobial agent administration or
when the infected lesion expands despite 2–3 days of
antimicrobial agent administration, the drugs must be
changed to other agents.
In the case of inappropriate antimicrobial activity of drugs
identiﬁed by bacterial cultures and susceptibility tests
On the basis of results of bacterial cultures and sensitivity
tests, appropriate antimicrobial drugs are selected. How-
ever, in many patients who have moderate or more severe
infections, these infections are likely to be mixed [10–15].
Therefore, antimicrobial drugs that cannot be broken down
by b-lactamase are selected.
Administration period of antimicrobial agents
In general, the administration period is 1 week for mild
cellulitis [24], and at least 1–2 weeks are needed for
moderate or more severe cases [4]. If clinical relief is not
recognized, the antimicrobial drugs are to be changed to
another type, with continued treatment taking into con-
sideration bacteria which are resistant to the antimicrobial
drugs used. An adequate administration period is essential
for patients with risk factors because they are apt to suffer
recurrences [4].
Necessity of surgical treatment
The necessity of surgical treatment must always be taken
into consideration. In the presence of pus retention,
drainage is conducted. In the presence of ischemic tissue,
debridement is required because not only do antimicrobial
agents fail to adequately penetrate tissue but the tissue
itself also constitutes an infected lesion. Local rest and
cooling are, of course, needed to treat infections, and in
extremely severe cases oxygen under high pressure (OHP)
therapy and administration of a granulocyte colony-
stimulating factor (G-CSF) preparation may also be
needed [25].
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